Repurposing tirbanibulin as an orally active E2‐targeting entry inhibitor against Chikungunya virus
British Journal of Pharmacology · 2026
DOI: 10.1111/bph.70642 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2026. Verfasst von Jing-Wen Gu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Chikungunya virus, Antiviral Agents, Drug Repositioning, Virus Internalization. Die Arbeit nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Rising Star Program.
Abstract (Originalsprache)
Background and purpose Chikungunya virus (CHIKV) causes severe acute and chronic disease, yet no approved specific antiviral treatment exists. To rapidly identify potential treatments, we aimed to screen an FDA‐approved drug library for inhibitors of CHIKV infection. Tirbanibulin, a dual‐microtubule polymerization and Src kinase inhibitor, was assessed for its potential anti‐CHIKV activity. Methods We performed a high‐throughput screen of an FDA‐approved drug library. Mechanism‐of‐action studies included entry‐step analysis, surface plasmon resonance (SPR) binding assays and molecular docking. In vivo efficacy was evaluated in lethal murine neuroinfection and CHIKV‐induced arthritis models following oral administration of the candidate compound. Experimental approach Tirbanibulin exhibited nanomolar to low‐micromolar antiviral activity (EC 50 range: 0.035–75.64 μM) across multiple cell lines, with high selective indices in key target HT22 and Huh7 cells. It acted at a post‐attachment entry step, inhibiting clathrin‐mediated endocytosis and potentially viral fusion. Surface plasmon resonance confirmed direct, high‐affinity binding to the CHIKV E1 and E2 glycoprotein complex (K_D = 73 nM). In the lethal neuroinfection model, oral tirbanibulin significantly improved survival and reduced brain viral loads; in the arthritis model, it markedly attenuated footpad swelling and inflammatory pathology. Conclusion and implications Tirbanibulin is a novel, orally bioavailable entry‐stage inhibitor that directly targets the E2 glycoprotein. Multiple preclinical and clinical studies have confirmed its favourable oral bioavailability and safety. Given its established clinical safety profile, it represents a promising repurposing candidate for clinical evaluation against Chikungunya fever.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai, China.
- Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai, China.
ORCID-Profile: Jing-Wen Gu, Yan-Hua He, Yu-Qing Ma, Wan-da Tang, Shu-Dan Luo, Hai-Lin Tang, Yan-Yong Yang, Fu Gao, Ping Zhao
Förderung
- National Natural Science Foundation of China
- Shanghai Rising Star Program
Zitieren
APA
Gu, J. W., He, Y. H., Ma, Y. Q., Tang, W. D., Luo, S. D., Tang, H. L., Yang, Y. Y., Gao, F., & Zhao, P. (2026). Repurposing tirbanibulin as an orally active E2‐targeting entry inhibitor against Chikungunya virus. British Journal of Pharmacology. https://doi.org/10.1111/bph.70642
Vancouver
Gu JW, He YH, Ma YQ, Tang WD, Luo SD, Tang HL, et al. Repurposing tirbanibulin as an orally active E2‐targeting entry inhibitor against Chikungunya virus. British Journal of Pharmacology. 2026. doi:10.1111/bph.70642
BibTeX
@article{Gu2026,
author = {Gu, Jing-Wen and He, Yan-Hua and Ma, Yu-Qing and Tang, Wan-da and Luo, Shu-Dan and Tang, Hai-Lin and Yang, Yan-Yong and Gao, Fu and Zhao, Ping},
title = {Repurposing tirbanibulin as an orally active E2‐targeting entry inhibitor against Chikungunya virus},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70642}
}
EUVIMED